Cytogen, Inc.
Research Cytogen, Inc. (217330.KQ) on Bullrun: market cap KRW 62.33B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker217330.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyKRW
- Market capKRW 62.33B
- Financial periodQ2 2026
- RevenueKRW 6.83B
- Net income-KRW 2.20B
- Free cash flow-KRW 1.09B
- Gross margin30.3%
Valuation Snapshot
latest market cap is KRW 62.33B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 62.33B | n/a | n/a | n/a |
Dividend history
About Cytogen, Inc.
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cytogen, Inc.'s market cap?
Cytogen, Inc.'s market capitalization is KRW 62.33B.
What does Cytogen, Inc. do?
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.